TY - JOUR
T1 - Tumor Cells Modulate Macrophage Phenotype in a Novel In Vitro Co-Culture Model of the NSCLC Tumor Microenvironment
AU - Park, Josiah Voth
AU - Chandra, Raghav
AU - Cai, Ling
AU - Ganguly, Debolina
AU - Li, Huiyu
AU - Toombs, Jason E.
AU - Girard, Luc
AU - Brekken, Rolf A.
AU - Minna, John D.
N1 - Funding Information:
This work was supported by the National Institutes of Health grants R01 CA243577 and U54 CA210181 (to Dr. Brekken); National Institutes of Health SPORE P50 CA070907, U54 CA224065, and CPRIT RP160652 (to Dr. Minna); the Effie Marie Cain Foundation (to Dr. Brekken), National Cancer Institute (NCI) T32 CA124334 (principal investigator: J. Shay) (to Dr. Park), Cancer Center Support Grant P30 CA142543 (Dr. Cai), and the Burroughs-Wellcome Fund (Dr. Chandra). The results published here are in part based on data generated by the TCGA Research Network: https://www.cancer.gov/tcga . The authors thank Novogene Bioinformatics Technology Co. Ltd. (Beijing, People’s Republic of China) for conducting the RNA sequencing, Simmons Cancer Center Tissue Resource (supported by NCI grant P30 CA142543), McDermott Sequencing, Microarray & Immune Phenotyping Core. The authors are indebted to Dr. Boning Gao for developing the patient-derived cancer-associated fibroblasts, Elizabeth McMillan for discussion and consultation on biostatistical analyses of this study, and Hyunsil Park for the assistance with mouse studies during the coronavirus disease 2019 pandemic and thank members of the Brekken and Minna laboratories for comments and advice during the development and execution of this project.
Publisher Copyright:
© 2022 International Association for the Study of Lung Cancer
PY - 2022/10
Y1 - 2022/10
N2 - Introduction: Macrophage phenotype in the tumor microenvironment correlates with prognosis in NSCLC. Immunosuppressive macrophages promote tumor progression, whereas proinflammatory macrophages may drive an antitumor immune response. How individual NSCLCs affect macrophage phenotype is a major knowledge gap. Methods: To systematically study the impact of lung cancer cells on macrophage phenotypes, we developed an in vitro co-culture model that consisted of molecularly and clinically annotated patient-derived NSCLC lines, human cancer-associated fibroblasts, and murine macrophages. Induced macrophage phenotype was studied through quantitative real-time polymerase chain reaction and validated in vivo using NSCLC xenografts through quantitative immunohistochemistry and clinically with The Cancer Genome Atlas (TCGA)–“matched” patient tumors. Results: A total of 72 NSCLC cell lines were studied. The most frequent highly induced macrophage-related gene was Arginase-1, reflecting an immunosuppressive M2-like phenotype. This was independent of multiple clinicopathologic factors, which also did not affect M2:M1 ratios in matched TCGA samples. In vivo, xenograft tumors established from high Arginase-1–inducing lines (Arghi) had a significantly elevated density of Arg1+ macrophages. Matched TCGA clinical samples to Arghi NSCLC lines had a significantly higher ratio of M2:M1 macrophages (p = 0.0361). Conclusions: In our in vitro co-culture model, a large panel of patient-derived NSCLC lines most frequently induced high-expression Arginase-1 in co-cultured mouse macrophages, independent of major clinicopathologic and oncogenotype-related factors. Arghi cluster-matched TCGA tumors contained a higher ratio of M2:M1 macrophages. Thus, this in vitro model reproducibly characterizes how individual NSCLC modulates macrophage phenotype, correlates with macrophage polarization in clinical samples, and can serve as an accessible platform for further investigation of macrophage-specific therapeutic strategies.
AB - Introduction: Macrophage phenotype in the tumor microenvironment correlates with prognosis in NSCLC. Immunosuppressive macrophages promote tumor progression, whereas proinflammatory macrophages may drive an antitumor immune response. How individual NSCLCs affect macrophage phenotype is a major knowledge gap. Methods: To systematically study the impact of lung cancer cells on macrophage phenotypes, we developed an in vitro co-culture model that consisted of molecularly and clinically annotated patient-derived NSCLC lines, human cancer-associated fibroblasts, and murine macrophages. Induced macrophage phenotype was studied through quantitative real-time polymerase chain reaction and validated in vivo using NSCLC xenografts through quantitative immunohistochemistry and clinically with The Cancer Genome Atlas (TCGA)–“matched” patient tumors. Results: A total of 72 NSCLC cell lines were studied. The most frequent highly induced macrophage-related gene was Arginase-1, reflecting an immunosuppressive M2-like phenotype. This was independent of multiple clinicopathologic factors, which also did not affect M2:M1 ratios in matched TCGA samples. In vivo, xenograft tumors established from high Arginase-1–inducing lines (Arghi) had a significantly elevated density of Arg1+ macrophages. Matched TCGA clinical samples to Arghi NSCLC lines had a significantly higher ratio of M2:M1 macrophages (p = 0.0361). Conclusions: In our in vitro co-culture model, a large panel of patient-derived NSCLC lines most frequently induced high-expression Arginase-1 in co-cultured mouse macrophages, independent of major clinicopathologic and oncogenotype-related factors. Arghi cluster-matched TCGA tumors contained a higher ratio of M2:M1 macrophages. Thus, this in vitro model reproducibly characterizes how individual NSCLC modulates macrophage phenotype, correlates with macrophage polarization in clinical samples, and can serve as an accessible platform for further investigation of macrophage-specific therapeutic strategies.
KW - In vitro co-culture model
KW - Macrophage phenotype
KW - Non–small cell lung cancer
KW - Tumor microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85135537122&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135537122&partnerID=8YFLogxK
U2 - 10.1016/j.jtho.2022.06.011
DO - 10.1016/j.jtho.2022.06.011
M3 - Article
C2 - 35798240
AN - SCOPUS:85135537122
SN - 1556-0864
VL - 17
SP - 1178
EP - 1191
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 10
ER -